Sandostatin LAR
( DrugBank: - / KEGG DRUG: - )
4 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
67 | Polycystic kidney disease | 1 |
77 | Growth hormone secreting pituitary adenoma | 40 |
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
84 | Sarcoidosis | 1 |
193 | Prader-Willi syndrome | 2 |
67. Polycystic kidney disease
Clinical trials : 233 / Drugs : 188 - (DrugBank : 54) / Drug target genes : 60 - Drug target pathways : 165
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
77. Growth hormone secreting pituitary adenoma
Clinical trials : 351 / Drugs : 241 - (DrugBank : 28) / Drug target genes : 26 - Drug target pathways : 87
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
84. Sarcoidosis
Clinical trials : 175 / Drugs : 189 - (DrugBank : 80) / Drug target genes : 74 - Drug target pathways : 177
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
193. Prader-Willi syndrome
Clinical trials : 128 / Drugs : 94 - (DrugBank : 25) / Drug target genes : 51 - Drug target pathways : 102
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|